Supreme Court Declines to Hear Pfizer’s Appeal in Celebrex Class Action

The U.S. Supreme Court has declined to hear Pfizer’s appeal of a class action shareholder lawsuit accusing the company of misrepresenting the results of a clinical study of its arthritis drug Celebrex. Pfizer had argued that the plaintiffs had failed to file their suit within the two-year statute of limitations. But the U.S. Court of Appeals for the Third Circuit disagreed in its ruling. The Supreme Court’s refusal to take up the appeal Monday means that the Third Circuit ruling stands.
Drug Industry Daily